TY - JOUR
T1 - Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica
AU - Akaishi, Tetsuya
AU - Nakashima, Ichiro
AU - Misu, Tatsuro
AU - Fujihara, Kazuo
AU - Aoki, Masashi
N1 - Funding Information:
I.N. reports personal fees from Mitsubishi Tanabe Pharma Corporation, Novartis Pharmaceuticals Japan, and grants from LSI Medience Corporation. T.M. has received speaker honoraria from Bayer Schering Pharma, Biogen Idec Japan, Mitsubishi Tanabe Pharma Corporation, Asahi Kasei Medical Co., and Astellas Pharma Inc. and research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Kuraray Medical Co., The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma, and Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology, and the Ministry of Health, Labor and Welfare of Japan. K.F. has received funding for travel and speaker honoraria from Bayer Schering Pharma, Biogen Idec, Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Asahi Kasei Medical Co., Daiichi Sankyo, and Nihon Pharmaceutical and research support from Bayer Schering Pharma, Biogen Idec Japan, Asahi Kasei Medical, The Chemo-Sero-Therapeutic Research Institute, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Nihon Pharmaceutical, and Genzyme Japan; he is funded as the secondary investigator (#22229008, 2010–2015) by the Grants-in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan and as the secondary investigator by the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan.
Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/6/15
Y1 - 2015/6/15
N2 - Depression and chronic fatigue are frequently present in multiple sclerosis (MS); however, the prevalence rates have not been investigated in neuromyelitis optica (NMO). Thirty-nine consecutive NMO and 75 MS patients were compared using self-rating questionnaires for depressive states, daily activity, and fatigue, as well as serum carnitine levels. A subgroup of patients with low carnitine levels were re-evaluated regarding depression and fatigue after levocarnitine treatment. Depression and fatigue were equally prevalent in MS and NMO and were strongly correlated with one another. Measurement of the serum carnitine levels and the administration of levocarnitine did not appear to be beneficial.
AB - Depression and chronic fatigue are frequently present in multiple sclerosis (MS); however, the prevalence rates have not been investigated in neuromyelitis optica (NMO). Thirty-nine consecutive NMO and 75 MS patients were compared using self-rating questionnaires for depressive states, daily activity, and fatigue, as well as serum carnitine levels. A subgroup of patients with low carnitine levels were re-evaluated regarding depression and fatigue after levocarnitine treatment. Depression and fatigue were equally prevalent in MS and NMO and were strongly correlated with one another. Measurement of the serum carnitine levels and the administration of levocarnitine did not appear to be beneficial.
KW - Carnitine
KW - Depression
KW - Fatigue
KW - Levocarnitine
KW - Neuromyelitis optica
UR - http://www.scopus.com/inward/record.url?scp=84929580984&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929580984&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2015.05.007
DO - 10.1016/j.jneuroim.2015.05.007
M3 - Article
C2 - 26004160
AN - SCOPUS:84929580984
SN - 0165-5728
VL - 283
SP - 70
EP - 73
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
ER -